German pharma major Bayer (BAYN: DE) has announced the opening of its new life science incubator, Bayer Co.Lab Shanghai.
Located in the Shanghai Innovation Park, part of China’s largest biopharma cluster in Zhangjiang, the site forms part of Bayer's global Co.Lab network, which includes hubs in the USA, Japan, and Germany.
The new facility is designed to foster collaboration within the biotechnology ecosystem, offering state-of-the-art laboratories, collaborative workspaces, and tailored support for start-ups, with the aim of boosting local innovation throughout the biopharma value chain.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze